Chief Executive Officer

Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience, spanning founding and building biotechnology companies, as well as working as a practicing physician. Most recently, he served as an executive at Corvidia Therapeutics where he was a founder, Chief Medical Officer and Chief Strategy Officer, guiding the company from seed stage through Series B and its lead asset through clinical proof of concept. Previously, he was Director for Emerging Innovations at AstraZeneca, responsible for preclinical through Phase 2 clinical studies both for compounds within the AstraZeneca pipeline and in support of compound out-licensing efforts. Dr. Kakkar has also served as an advisor to life sciences venture firms. He continues to practice medicine as Associate Physician at Brigham and Woman’s Hospital and is a Lecturer in Medicine at Harvard Medical School. Dr. Kakkar is dual-trained via the American Board of Internal Medicine Fast Track program in molecular biology and clinical cardiology. He received his BA from Tufts University and MD from the Tufts School of Medicine where he was a junior inductee of the Alpha Omega Alpha society. He is a fellow of the American College of Cardiology.